Level Zero Health, Inc.

Level Zero Health develops innovative wearable technology focused on continuous hormone monitoring, enhancing reproductive health management with real-time data insights and user-friendly design. Founded in 2023 and based in San Francisco, US, Level Zero Health is dedicated to advancing reproductive health through wearable technology. The company successfully closed 2 deals, with its most recent funding round occurring on 18th February 2025. This funding, amounting to GBP 5.

5 million, was led by Redalpine, alongside participation from Entrepreneur First and SOSV. The founder has a background in health technology startups, although specific prior ventures are not disclosed. Level Zero Health specializes in advanced wearable technology designed for continuous hormone monitoring. The core product employs DNA-based sensors to provide real-time insights into hormonal changes, aiming to revolutionize reproductive health management by making hormone data as accessible as metrics like heart rate and step counts.

The minimally invasive device prioritizes user comfort, allowing seamless integration into daily life. Targeting health-conscious individuals, the products cater to both consumers and healthcare providers, primarily focusing on markets in North America and parts of Europe. Level Zero Health's revenue structure is centered around direct consumer sales of its wearable hormone monitoring devices. The company has established a subscription model for ongoing data analysis and personalized insights, enhancing the value proposition of their flagship product.

Customers typically engage with Level Zero Health through direct-to-consumer channels, purchasing the wearable device and opting for a subscription service that provides continuous monitoring and detailed reports on hormone levels. This business model facilitates recurring revenue through subscription renewals while fostering customer loyalty through enhanced service offerings. In February 2025, Level Zero Health raised GBP 5. 5 million in pre-seed funding, which will be utilized to develop a remote and continuous hormone monitor using DNA-based sensors.

The company aims to launch new products that enhance hormone monitoring capabilities by mid-2026, with plans for expansion into additional European markets by the end of 2025. This strategic initiative is expected to broaden their consumer base and strengthen their presence in the health technology sector.